晚期宫颈癌患者行白蛋白结合型紫杉醇联合顺铂治疗前后的变化分析  

Analysis of changes in patients with advanced cervical cancer before and after treatment with albumin-bound paclitaxel combined with cisplatin

作　　者：林佳[1] 王丹丹 林庆纯 陈斌[1] 庄梅生[1] LIN Jia;WANG Dan-dan;LIN Qing-chun(Department of Radiotherapy,Jieyang People's Hospital,Jieyang 522000,China)

机构地区：[1]揭阳市人民医院放疗科,522000

出　　处：《中国实用医药》2024年第9期94-98,共5页China Practical Medicine

摘　　要：目的 分析晚期宫颈癌患者行白蛋白结合型紫杉醇联合顺铂治疗前后的变化。方法 100例晚期宫颈癌患者,随机分为研究组和对照组,每组50例。两组患者均接受规定治疗方案同步放化疗,研究组使用注射用紫杉醇(白蛋白结合型)联合顺铂化疗治疗,对照组采用溶剂型紫杉醇联合顺铂化疗治疗。比较两组患者病情缓解程度、毒副反应发生情况(血红蛋白降低、血小板减少、白细胞减少、中性粒细胞减少、胃肠道反应、肝功能异常)、治疗前后肿瘤标志物指标[癌胚抗原(CEA)、鳞状细胞癌抗原(SCC-Ag)、细胞角蛋白19片段抗原(CYFRA21-1)、糖类抗原125(CA125)]水平、2年内病情恶化、生存情况。结果 研究组治疗后的病情总缓解率66.00%高于对照组的46.00%,差异有统计学意义(P<0.05)。研究组胃肠道反应发生率16.00%低于对照组的34.00%,差异有统计学意义(P<0.05)。治疗后,研究组患者CEA(8.05±1.19)U/ml、SCC-Ag(1.86±0.41)ng/ml、CYFRA21-1(8.11±1.52)ng/ml、CA125(26.32±2.86)U/ml均低于对照组的(8.86±1.38)U/ml、(2.13±0.49)ng/ml、(9.03±1.85)ng/ml、(27.64±3.13)U/ml,差异有统计学意义(P<0.05)。研究组治疗后2年内的病情恶化率46.00%低于对照组的66.00%,生存率82.00%高于对照组的64.00%,恶化时间(1.15±0.54)年、死亡时间(1.48±0.46)年均晚于对照组的(0.91±0.52)、(1.23±0.45)年,差异有统计学意义(P<0.05)。结论 给予晚期宫颈癌患者白蛋白结合型紫杉醇联合顺铂治疗可增加病灶缓解程度,减少胃肠道反应,降低治疗后短期内的病情恶化发生率,同时提高患者生存能力。Objective To analyze the changes in patients with advanced cervical cancer before and after treatment with albumin-bound paclitaxel combined with cisplatin.Methods 100 patients with advanced cervical cancer were randomly divided into a study group and a control group,with 50 cases in each group.Both groups received the prescribed treatment regimen of simultaneous chemoradiotherapy.The study group was treated with paclitaxel injection(albumin-bound)in combination with cisplatin chemotherapy,while the control group was treated with solvent-based paclitaxel in combination with cisplatin chemotherapy.Patients in both groups were compared in terms of severity of disease remission,occurrence of adverse reactions(decreased hemoglobin,thrombocytopenia,leukopenia,neutropenia,gastrointestinal reaction,abnormal liver function),tumor markers[carcinoembryonic antigen(CEA),squamous cell carcinoma antigen(SCC-Ag),and cytokeratin 19 fragment antigen 21-1(CYFRA21-1)before and after treatment,carbohydrate antigen 125(CA125)]level,disease deterioration and survival within 2 years.Results After treatment,the total remission rate of the treatment group was 66.00%,which was higher than 46.00%of the control group,and the difference was statistically significant(P<0.05).The incidence of gastrointestinal reactions in the study group was 16.00%,which was lower than 34.00%in the control group,and the difference was statistically significant(P<0.05).After treatment,the study group had CEA of(8.05±1.19)U/ml,SCC-Ag of(1.86±0.41)ng/ml,CYFRA21-1 of(8.11±1.52)ng/ml,and CA125 of(26.32±2.86)U/ml,which were lower than(8.86±1.38)U/ml,(2.13±0.49)ng/ml,(9.03±1.85)ng/ml,and(27.64±3.13)U/ml in the control group.The difference was statistically significant(P<0.05).The deterioration rate of the study group within 2 years after treatment was 46.00%,which was lower than 66.00%of the control group;the survival rate of the study group was 82.00%,which was higher than 64.00%of the control group;the time to deterioration of the study group was(1.15±0.5

关 键 词：晚期宫颈癌 白蛋白结合型紫杉醇 顺铂 放疗 

分 类 号：R737.33[医药卫生—肿瘤]